language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
CBUSCBUS

$1.89

-0.06
arrow_drop_down3.08%
Current Market·update15 Jan 2026 17:44
Day's Range
1.89-1.98
52-week Range
1.09-3.4

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-13
Next Earnings TimeAfter Market Close
Volume54.43K
Average Volume 30d244.69K

AI CBUS Summary

Powered by LiveAI
💰
-0.3
Valuation (P/E Ratio)
Negative P/E due to net losses. Indicates the company is not currently profitable.
📈
-12.59
EPS Growth (YoY)
Significant year-over-year decline in EPS, reflecting ongoing losses.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Hold
40

Cibus, Inc. operates in the promising agricultural biotechnology sector, leveraging gene editing technology. However, current financial performance indicates significant losses and negative cash flow, with a high burn rate. While the long-term thematic potential is strong, the company's current financial health and recent significant stock price decline warrant a cautious approach.

Strong

Thematic

75

Cibus is positioned to benefit from the growing demand for sustainable agriculture, reduced chemical usage, and the development of low-carbon plant products through its gene editing technology. The focus on both trait productivity and sustainable ingredients addresses key global agricultural challenges.

Weak

Fundamental

30

Financially, Cibus is in a challenging phase. It shows minimal revenue, substantial operating losses, and a significant negative free cash flow. The company's cash position is dwindling, and the burn rate is high, suggesting a need for future funding or a significant shift in operational efficiency.

Bearish

Technical

30

Recent price action and technical indicators suggest a strong downtrend. The stock has experienced significant price drops over various periods, and most short-to-medium term moving averages indicate selling pressure. The MACD and RSI also suggest bearish momentum.

FactorScore
Sustainable Agriculture Trends90
Biotechnology Innovation85
Low-Carbon Solutions70
Company Rebranding65
Regulatory Landscape for Gene Editing55
FactorScore
Valuation20
Profitability5
Growth70
Balance Sheet Health30
Cash Flow10
FactorScore
Trend Analysis20
Momentum40
Volume Confirmation40
Support & Resistance30
MACD30

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (5)

Valuation chevron_right

Low Price-to-Sales Ratio

The current Price-to-Sales (P/S) ratio is 20.6, which, while seemingly high, should be considered in the context of a growth-oriented biotechnology company. Examining the historical P/S trend for CBUS is crucial. The trailing P/S of 20.6 is lower than the previous year's 42.9, indicating potential improvement or a market re-evaluation.

Company Profile chevron_right

Focus on Gene Editing Technology

Cibus Inc. is an agricultural biotechnology company developing and licensing gene-edited plant traits. This focus on innovative technology in the agricultural sector could offer significant long-term growth potential as the demand for sustainable and productive agriculture increases.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation chevron_right

High Negative Earnings Per Share (EPS)

The company consistently reports significant negative EPS (e.g., -0.74 in Q2 2025, -0.87 in Q1 2025, -12.59 in Q1 2024). A Price-to-Earnings (P/E) ratio is not applicable in its standard form due to losses. The Price-to-Sales (P/S) ratio is high, especially considering the current revenue and losses.

Growth and Profitability chevron_right

Significant Net Losses

Cibus Inc. has incurred substantial net losses in recent periods (e.g., -$251.39M in 2024Q4, -$267.63M in 2023Q4). The negative net margins (e.g., -5898.4% in 2024Q4) highlight a significant challenge in achieving profitability.

Show More 🔒

Calendar

August 2025

7

Next Earnings Date

EPS Est.
Revenue Est.

H: $-0.33

A: $-0.33

L: $-0.33

H: 1.26M

A: 1.15M

L: 1.05M

Profile

Websitecibus.com
Employees (FY)157
ISINUS17166A1016
FIGI-

Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California.

Seasonals

2025
2024
2023
2022
2021

Price Target

16.38 USD

The 39 analysts offering 1 year price forecasts for CBUS have a max estimate of 25.00 and a min estimate of 2.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
21.8M (45.02%)
Closely held shares
26.6M (54.98%)
48.4M
Free Float shares
21.8M (45.02%)
Closely held shares
26.6M (54.98%)

Capital Structure

Market cap
77.9M
Debt
36.29M
Minority interest
0.00
Cash & equivalents
14.43M
Enterprise value
99.76M

Valuation - Summary

Market Cap
80.7M
Net income
-250M(-309.89%)
Revenue
3.91M(4.85%)
80.7M
Market Cap
80.7M
Net income
-250M(-309.89%)
Revenue
3.91M(4.85%)
Price to earning ratio (P/E)-0.30x
Price to sales ratio (P/S)20.60x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
4.26M
COGS
0.00
Gross Profit
4.26M
OpEx
81.23M
Operating Income
-76.96M
Other & Taxes
174.42M
Net Income
-251.39M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒